临床获益-话题@MedSci

#临床获益#

27篇内容 | 781人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2040414, encodeId=fe342040414ca, content=<a href='/topic/show?id=1f61229925d' target=_blank style='color:#2F92EE;'>#临床获益#</a>, objectTitle=预约领U盘：血压、MAU 双达标，全面心肾保护——安博维对高血压患者的临床获益, objectType=article, longId=739733, objectId=4a4de3973319, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4a4de3973319, replyNumber=0, likeNumber=23, createdTime=2023-02-03, rootId=0, userName=heli0118, userId=21015, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4a4de3973319, moduleTitle=预约领U盘：血压、MAU 双达标，全面心肾保护——安博维对高血压患者的临床获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4a4de3973319)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2040413, encodeId=7f4620404136f, content=<a href='/topic/show?id=1f61229925d' target=_blank style='color:#2F92EE;'>#临床获益#</a>, objectTitle=ESMO 2022：Trastuzumab Deruxtecan在转移性胃癌/GEJ癌中维持临床获益（DESTINY-Gastric02研究）, objectType=article, longId=739074, objectId=6781e3907456, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6781e3907456, replyNumber=0, likeNumber=37, createdTime=2022-09-24, rootId=0, userName=heli0118, userId=21015, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6781e3907456, moduleTitle=ESMO 2022：Trastuzumab Deruxtecan在转移性胃癌/GEJ癌中维持临床获益（DESTINY-Gastric02研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6781e3907456)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2040412, encodeId=07f62040412fc, content=<a href='/topic/show?id=1f61229925d' target=_blank style='color:#2F92EE;'>#临床获益#</a>, objectTitle=中国亚组数据正式揭晓：泰瑞沙®用于早期EGFR突变肺癌患者辅助治疗，进一步证实中国人群临床获益, objectType=article, longId=301654, objectId=d9c830165485, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d9c830165485, replyNumber=0, likeNumber=32, createdTime=2022-04-04, rootId=0, userName=heli0118, userId=21015, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d9c830165485, moduleTitle=中国亚组数据正式揭晓：泰瑞沙®用于早期EGFR突变肺癌患者辅助治疗，进一步证实中国人群临床获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d9c830165485)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2040411, encodeId=dc1d2040411f1, content=<a href='/topic/show?id=1f61229925d' target=_blank style='color:#2F92EE;'>#临床获益#</a>, objectTitle=Blood：T细胞淋巴瘤患者采用鲁索替尼靶向抑制JAK/STAT的临床获益情况, objectType=article, longId=293570, objectId=cf392935e0e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cf392935e0e0, replyNumber=0, likeNumber=35, createdTime=2022-12-06, rootId=0, userName=heli0118, userId=21015, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cf392935e0e0, moduleTitle=Blood：T细胞淋巴瘤患者采用鲁索替尼靶向抑制JAK/STAT的临床获益情况, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cf392935e0e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2040409, encodeId=a6f520404096d, content=<a href='/topic/show?id=1f61229925d' target=_blank style='color:#2F92EE;'>#临床获益#</a>, objectTitle=Heart：真实世界分析全新结果，再次证实了非维生素K拮抗剂口服抗凝剂的临床获益及安全性, objectType=article, longId=207716, objectId=b66220e716e3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b66220e716e3, replyNumber=0, likeNumber=42, createdTime=2021-09-14, rootId=0, userName=朱睿睿, userId=a57b78, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b66220e716e3, moduleTitle=Heart：真实世界分析全新结果，再次证实了非维生素K拮抗剂口服抗凝剂的临床获益及安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b66220e716e3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2040410, encodeId=0900204041069, content=<a href='/topic/show?id=1f61229925d' target=_blank style='color:#2F92EE;'>#临床获益#</a>, objectTitle=中国自主创新微球制剂瑞欣妥®上市，以全球领先微球技术提升精神分裂症临床获益, objectType=article, longId=209472, objectId=64002094e27d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=64002094e27d, replyNumber=0, likeNumber=0, createdTime=2021-05-11, rootId=0, userName=heli0118, userId=21015, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=64002094e27d, moduleTitle=中国自主创新微球制剂瑞欣妥®上市，以全球领先微球技术提升精神分裂症临床获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=64002094e27d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2040408, encodeId=11c820404080d, content=<a href='/topic/show?id=1f61229925d' target=_blank style='color:#2F92EE;'>#临床获益#</a>, objectTitle=JCO：北大肿瘤医院3期试验揭示多科室联合治疗转移性胃癌的临床获益, objectType=article, longId=205673, objectId=6fbf2056e3fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6fbf2056e3fc, replyNumber=0, likeNumber=48, createdTime=2021-11-08, rootId=0, userName=朱睿睿, userId=a57b78, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6fbf2056e3fc, moduleTitle=JCO：北大肿瘤医院3期试验揭示多科室联合治疗转移性胃癌的临床获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6fbf2056e3fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2040406, encodeId=2c18204040604, content=<a href='/topic/show?id=1f61229925d' target=_blank style='color:#2F92EE;'>#临床获益#</a>, objectTitle=PD-1单抗Opdivo新辅助治疗非小细胞肺癌，3期临床获益, objectType=article, longId=201929, objectId=558820192924, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=558820192924, replyNumber=0, likeNumber=29, createdTime=2021-03-23, rootId=0, userName=朱睿睿, userId=a57b78, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=558820192924, moduleTitle=PD-1单抗Opdivo新辅助治疗非小细胞肺癌，3期临床获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=558820192924)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2040407, encodeId=043b204040e30, content=<a href='/topic/show?id=1f61229925d' target=_blank style='color:#2F92EE;'>#临床获益#</a>, objectTitle=Clin Cancer Res：联用地塞米松会降低接受免疫疗法的胶质瘤患者临床获益, objectType=article, longId=204942, objectId=51a42049425e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=51a42049425e, replyNumber=0, likeNumber=42, createdTime=2021-09-13, rootId=0, userName=朱睿睿, userId=a57b78, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=51a42049425e, moduleTitle=Clin Cancer Res：联用地塞米松会降低接受免疫疗法的胶质瘤患者临床获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=51a42049425e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2040405, encodeId=83122040405db, content=<a href='/topic/show?id=1f61229925d' target=_blank style='color:#2F92EE;'>#临床获益#</a>, objectTitle=NAT MED：血清IL-8升高与肿瘤内中性粒细胞增多和免疫检查点抑制剂的临床获益降低有关 , objectType=article, longId=194254, objectId=3e7b19425425, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3e7b19425425, replyNumber=0, likeNumber=54, createdTime=2020-12-01, rootId=0, userName=朱睿睿, userId=a57b78, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3e7b19425425, moduleTitle=NAT MED：血清IL-8升高与肿瘤内中性粒细胞增多和免疫检查点抑制剂的临床获益降低有关 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3e7b19425425)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2040404, encodeId=3f312040404c9, content=<a href='/topic/show?id=1f61229925d' target=_blank style='color:#2F92EE;'>#临床获益#</a>, objectTitle=Nat Med：IL-8与PD-L1抑制剂在泌尿系肿瘤的临床获益减少有关, objectType=article, longId=194253, objectId=349a19425314, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=349a19425314, replyNumber=0, likeNumber=33, createdTime=2020-05-29, rootId=0, userName=朱睿睿, userId=a57b78, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=349a19425314, moduleTitle=Nat Med：IL-8与PD-L1抑制剂在泌尿系肿瘤的临床获益减少有关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=349a19425314)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2040403, encodeId=5a102040403b2, content=<a href='/topic/show?id=1f61229925d' target=_blank style='color:#2F92EE;'>#临床获益#</a>, objectTitle=PLK1抑制剂Onvasertib治疗KRAS突变的mCRC患者：肿瘤消退和临床获益, objectType=article, longId=186925, objectId=3f7618692587, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3f7618692587, replyNumber=0, likeNumber=26, createdTime=2020-09-24, rootId=0, userName=朱睿睿, userId=a57b78, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3f7618692587, moduleTitle=PLK1抑制剂Onvasertib治疗KRAS突变的mCRC患者：肿瘤消退和临床获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3f7618692587)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2040402, encodeId=618d204040291, content=<a href='/topic/show?id=1f61229925d' target=_blank style='color:#2F92EE;'>#临床获益#</a>, objectTitle=帕博利珠单抗二线治疗肝癌虽未达统计学意义但显示临床获益, objectType=article, longId=168158, objectId=24ab168158c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=24ab168158c3, replyNumber=0, likeNumber=43, createdTime=2020-01-28, rootId=0, userName=朱睿睿, userId=a57b78, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=24ab168158c3, moduleTitle=帕博利珠单抗二线治疗肝癌虽未达统计学意义但显示临床获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=24ab168158c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2040401, encodeId=e69820404017f, content=<a href='/topic/show?id=1f61229925d' target=_blank style='color:#2F92EE;'>#临床获益#</a>, objectTitle=李建军：药物机制是PCSK9抑制剂临床获益的有力保证, objectType=article, longId=148232, objectId=5995148232b3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5995148232b3, replyNumber=0, likeNumber=49, createdTime=2019-03-11, rootId=0, userName=朱睿睿, userId=a57b78, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5995148232b3, moduleTitle=李建军：药物机制是PCSK9抑制剂临床获益的有力保证, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5995148232b3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2040400, encodeId=7a43204040045, content=<a href='/topic/show?id=1f61229925d' target=_blank style='color:#2F92EE;'>#临床获益#</a>, objectTitle=JAMA Cardiol：全新血脂Meta分析支持LDL-C“越低越好”，临床获益来自降脂本身, objectType=article, longId=146073, objectId=79771460e36c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=79771460e36c, replyNumber=0, likeNumber=31, createdTime=2018-10-05, rootId=0, userName=朱睿睿, userId=a57b78, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=79771460e36c, moduleTitle=JAMA Cardiol：全新血脂Meta分析支持LDL-C“越低越好”，临床获益来自降脂本身, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=79771460e36c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2040399, encodeId=c086204039902, content=<a href='/topic/show?id=1f61229925d' target=_blank style='color:#2F92EE;'>#临床获益#</a>, objectTitle=CLIN CANCER RES：p95HER2可以预测Trastuzumab辅助治疗临床获益, objectType=article, longId=142350, objectId=1ea3142350bb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1ea3142350bb, replyNumber=0, likeNumber=30, createdTime=2018-11-23, rootId=0, userName=朱睿睿, userId=a57b78, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1ea3142350bb, moduleTitle=CLIN CANCER RES：p95HER2可以预测Trastuzumab辅助治疗临床获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1ea3142350bb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2040397, encodeId=6601204039e6e, content=<a href='/topic/show?id=1f61229925d' target=_blank style='color:#2F92EE;'>#临床获益#</a>, objectTitle=Lancet Infect Dis：流感：奥司他韦联合抗病毒治疗比单药临床获益更多？, objectType=article, longId=127810, objectId=b97612e810f8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b97612e810f8, replyNumber=0, likeNumber=36, createdTime=2018-07-25, rootId=0, userName=朱睿睿, userId=a57b78, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b97612e810f8, moduleTitle=Lancet Infect Dis：流感：奥司他韦联合抗病毒治疗比单药临床获益更多？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b97612e810f8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2040398, encodeId=99b22040398b2, content=<a href='/topic/show?id=1f61229925d' target=_blank style='color:#2F92EE;'>#临床获益#</a>, objectTitle=JAHA：我国≥75岁PCI患者负荷双联抗血小板治疗无临床获益且出血风险增加, objectType=article, longId=134286, objectId=4bf7134286bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4bf7134286bd, replyNumber=0, likeNumber=30, createdTime=2019-01-25, rootId=0, userName=朱睿睿, userId=a57b78, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4bf7134286bd, moduleTitle=JAHA：我国≥75岁PCI患者负荷双联抗血小板治疗无临床获益且出血风险增加, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4bf7134286bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2040394, encodeId=1884204039474, content=<a href='/topic/show?id=1f61229925d' target=_blank style='color:#2F92EE;'>#临床获益#</a>, objectTitle=JCO：抗癌药物评价工具的临床获益如何？, objectType=article, longId=101364, objectId=fb521013644a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fb521013644a, replyNumber=0, likeNumber=0, createdTime=2017-11-04, rootId=0, userName=朱睿睿, userId=a57b78, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fb521013644a, moduleTitle=JCO：抗癌药物评价工具的临床获益如何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fb521013644a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2040395, encodeId=21f420403950e, content=<a href='/topic/show?id=1f61229925d' target=_blank style='color:#2F92EE;'>#临床获益#</a>, objectTitle=Lancet：ACS患者PCI术后，由普拉格雷调整为氯吡格雷维持应用12个月临床获益更佳, objectType=article, longId=111185, objectId=e1b3111185dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e1b3111185dd, replyNumber=0, likeNumber=34, createdTime=2017-11-24, rootId=0, userName=朱睿睿, userId=a57b78, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e1b3111185dd, moduleTitle=Lancet：ACS患者PCI术后，由普拉格雷调整为氯吡格雷维持应用12个月临床获益更佳, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e1b3111185dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

临床获益

2020-05-29

heli0118 (审核中...)

前往app查看评论内容

#临床获益#

预约领U盘：血压、MAU 双达标，全面心肾保护——安博维对高血压患者的临床获益

2023-02-03

heli0118 (审核中...)

前往app查看评论内容

#临床获益#

ESMO 2022：Trastuzumab Deruxtecan在转移性胃癌/GEJ癌中维持临床获益（DESTINY-Gastric02研究）

2022-09-24

heli0118 (审核中...)

前往app查看评论内容

#临床获益#

中国亚组数据正式揭晓：泰瑞沙®用于早期EGFR突变肺癌患者辅助治疗，进一步证实中国人群临床获益

2022-04-04

heli0118 (审核中...)

前往app查看评论内容

#临床获益#

Blood：T细胞淋巴瘤患者采用鲁索替尼靶向抑制JAK/STAT的临床获益情况

2022-12-06

朱睿睿 (审核中...)

前往app查看评论内容

#临床获益#

Heart：真实世界分析全新结果，再次证实了非维生素K拮抗剂口服抗凝剂的临床获益及安全性

2021-09-14

heli0118 (审核中...)

前往app查看评论内容

#临床获益#

中国自主创新微球制剂瑞欣妥®上市，以全球领先微球技术提升精神分裂症临床获益

2021-05-11

朱睿睿 (审核中...)

前往app查看评论内容

#临床获益#

JCO：北大肿瘤医院3期试验揭示多科室联合治疗转移性胃癌的临床获益

2021-11-08

朱睿睿 (审核中...)

前往app查看评论内容

#临床获益#

PD-1单抗Opdivo新辅助治疗非小细胞肺癌，3期临床获益

2021-03-23

朱睿睿 (审核中...)

前往app查看评论内容

#临床获益#

Clin Cancer Res：联用地塞米松会降低接受免疫疗法的胶质瘤患者临床获益

2021-09-13

朱睿睿 (审核中...)

前往app查看评论内容

#临床获益#

NAT MED：血清IL-8升高与肿瘤内中性粒细胞增多和免疫检查点抑制剂的临床获益降低有关

2020-12-01

朱睿睿 (审核中...)

前往app查看评论内容

#临床获益#

Nat Med：IL-8与PD-L1抑制剂在泌尿系肿瘤的临床获益减少有关

2020-05-29

朱睿睿 (审核中...)

前往app查看评论内容

#临床获益#

PLK1抑制剂Onvasertib治疗KRAS突变的mCRC患者：肿瘤消退和临床获益

2020-09-24

朱睿睿 (审核中...)

前往app查看评论内容

#临床获益#

帕博利珠单抗二线治疗肝癌虽未达统计学意义但显示临床获益

2020-01-28

朱睿睿 (审核中...)

前往app查看评论内容

#临床获益#

李建军：药物机制是PCSK9抑制剂临床获益的有力保证

2019-03-11

朱睿睿 (审核中...)

前往app查看评论内容

#临床获益#

JAMA Cardiol：全新血脂Meta分析支持LDL-C“越低越好”，临床获益来自降脂本身

2018-10-05

朱睿睿 (审核中...)

前往app查看评论内容

#临床获益#

CLIN CANCER RES：p95HER2可以预测Trastuzumab辅助治疗临床获益

2018-11-23

朱睿睿 (审核中...)

前往app查看评论内容

#临床获益#

Lancet Infect Dis：流感：奥司他韦联合抗病毒治疗比单药临床获益更多？

2018-07-25

朱睿睿 (审核中...)

前往app查看评论内容

#临床获益#

JAHA：我国≥75岁PCI患者负荷双联抗血小板治疗无临床获益且出血风险增加

2019-01-25

朱睿睿 (审核中...)

前往app查看评论内容

#临床获益#

JCO：抗癌药物评价工具的临床获益如何？

2017-11-04

朱睿睿 (审核中...)

前往app查看评论内容

#临床获益#

Lancet：ACS患者PCI术后，由普拉格雷调整为氯吡格雷维持应用12个月临床获益更佳

2017-11-24

科室
- - 订阅+
  - 更多科室
工具
服务